175 related articles for article (PubMed ID: 32367180)
1. Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.
González-Barca E; Capote FJ; Gómez-Codina J; Panizo C; Salar A; Sancho JM; López A; Briones J; Muñoz A; Encuentra M; Mercadal S; Domingo-Domenech E; de Sevilla AF;
Ann Hematol; 2021 Apr; 100(4):1023-1029. PubMed ID: 32367180
[TBL] [Abstract][Full Text] [Related]
2. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU; Dierickx D; Zimmermann H; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Salles G; Kliem V; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S
J Clin Oncol; 2017 Feb; 35(5):536-543. PubMed ID: 27992268
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients.
Berney T; Delis S; Kato T; Nishida S; Mittal NK; Madariaga J; Levi D; Nery JR; Cirocco RE; Gelman B; Ruiz P; Tzakis AG
Transplantation; 2002 Oct; 74(7):1000-6. PubMed ID: 12394845
[TBL] [Abstract][Full Text] [Related]
5. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
6. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
[TBL] [Abstract][Full Text] [Related]
7. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
[TBL] [Abstract][Full Text] [Related]
8. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
Chen DB; Wang Y; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
[TBL] [Abstract][Full Text] [Related]
9. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.
Gross TG; Orjuela MA; Perkins SL; Park JR; Lynch JC; Cairo MS; Smith LM; Hayashi RJ
Am J Transplant; 2012 Nov; 12(11):3069-75. PubMed ID: 22883417
[TBL] [Abstract][Full Text] [Related]
10. Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.
Zimmermann H; Nitsche M; Pott C; Reinke P; Babel N; Hermann RM; Hauser IA; Hahn D; Ritgen M; Pietschmann C; Klapper W; Anagnostopoulos I; Trappe RU;
Ann Hematol; 2021 Aug; 100(8):2043-2050. PubMed ID: 33973053
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.
Choquet S; Leblond V; Herbrecht R; Socié G; Stoppa AM; Vandenberghe P; Fischer A; Morschhauser F; Salles G; Feremans W; Vilmer E; Peraldi MN; Lang P; Lebranchu Y; Oksenhendler E; Garnier JL; Lamy T; Jaccard A; Ferrant A; Offner F; Hermine O; Moreau A; Fafi-Kremer S; Morand P; Chatenoud L; Berriot-Varoqueaux N; Bergougnoux L; Milpied N
Blood; 2006 Apr; 107(8):3053-7. PubMed ID: 16254143
[TBL] [Abstract][Full Text] [Related]
12. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment.
Chan TS; Hwang YY; Gill H; Au WY; Leung AY; Tse E; Chim CS; Loong F; Kwong YL
Clin Transplant; 2012; 26(5):679-83. PubMed ID: 22324300
[TBL] [Abstract][Full Text] [Related]
13. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
15. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation.
Zilz ND; Olson LJ; McGregor CG
J Heart Lung Transplant; 2001 Jul; 20(7):770-2. PubMed ID: 11448808
[TBL] [Abstract][Full Text] [Related]
16. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
17. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
[TBL] [Abstract][Full Text] [Related]
20. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication.
Verschuuren EA; Stevens SJ; van Imhoff GW; Middeldorp JM; de Boer C; Koëter G; The TH; van Der Bij W
Transplantation; 2002 Jan; 73(1):100-4. PubMed ID: 11792987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
